title: Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
abstract: Clofarabine (Clo), fludarabine (Flu), and busulfan (Bu) are used in pretransplantation conditioning therapy for patients with myeloid leukemia. To further improve their efficacy in FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD)-positive acute myeloid leukemia (AML), we investigated their synergism with sorafenib (Sor). Exposure of FLT3-ITD-positive MV-4-11 and MOLM 13 cells to Bu+Clo+Flu+Sor resulted in synergistic cytotoxicity; no such synergism was observed in the FLT3-wild type THP-1 and KBM3/Bu250(6) cell lines. The drug synergism in MV-4-11 cells could be attributed to activation of DNA damage response, histone 3 modifications, inhibition of prosurvival kinases, and activation of apoptosis. Further, the phosphorylation of kinases, including FLT3, MAPK kinase (MEK), and AKT, was inhibited. The FLT3-ITD substrate STAT5 and its target gene PIM 2 product decreased when cells were exposed to Sor alone, Bu+Clo+Flu, and Bu+Clo+Flu+Sor. The level of the proapoptotic protein p53 upregulated modulator of apoptosis (PUMA) increased, whereas the level of prosurvival protein MCL-1 decreased when cells were exposed to Bu+Clo+Flu+Sor. The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were exposed to Bu+Clo+Flu or Bu+Clo+Flu+Sor. The changes in the level of these proteins, which are involved in mitochondrial control of apoptosis, correlate with changes in mitochondrial membrane potential. Bu+Clo+Flu+Sor decreased mitochondrial membrane potential by 60% and caused leakage of cytochrome c, second mitochondria-derived activator of caspases (SMAC)/direct IAP Binding protein with low pI (DIABLO), and AIF from the mitochondria to the cytoplasm, caspase activation, and cell death, suggesting the activation of apoptosis. Analogous, synergistic cytotoxicity in response to Bu, Clo, Flu, and Sor was observed in mononuclear cells isolated from FLT3-ITD-positive AML patients. Although our previous studies were aimed at standardizing the conditioning regimen, the new findings suggest that patients with abnormal expression of FLT3 might further benefit from individualizing treatment through the addition of Sor to Bu+Clo+Flu, thereby providing personalized pretransplantation therapy.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Guiyun
authors.initials: G
authors.lastname: Song
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Benigno C
authors.initials: BC
authors.lastname: Valdez
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: bandersson@mdanderson.org.
authors.forename: Borje S
authors.initials: BS
authors.lastname: Andersson
mesh_terms: D000227:Adenine Nucleotides / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000494:pharmacology*; D002066:Busulfan / Q000008:administration & dosage / Q000494:pharmacology*; D000077866:Clofarabine; D004249:DNA Damage; D004357:Drug Synergism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D010766:Phosphorylation; D000077157:Sorafenib; D020080:Tandem Repeat Sequences; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077866:Clofarabine; D000077157:Sorafenib; D051941:fms-Like Tyrosine Kinase 3; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine
keywords: Acute myeloid leukemia; Busulfan; Clofarabine; FLT3; Fludarabine; Sorafenib
references.citation: Blood. 2005 Jun 15;105(12):4792-9
references.pmid: 15718420
references.citation: Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900
references.pmid: 20946966
references.citation: Biochem Pharmacol. 2011 Jan 15;81(2):222-32
references.pmid: 20933509
references.citation: Blood. 2002 Sep 1;100(5):1810-6
references.pmid: 12176904
references.citation: Expert Opin Investig Drugs. 2011 Oct;20(10):1377-95
references.pmid: 21895538
references.citation: Nature. 2012 Apr 15;485(7397):260-3
references.pmid: 22504184
references.citation: Leuk Res. 2011 Mar;35(3):422-3
references.pmid: 21093053
references.citation: Mol Pharmacol. 2007 Sep;72(3):788-95
references.pmid: 17595328
references.citation: Oncologist. 2011;16(8):1162-74
references.pmid: 21765192
references.citation: J Biol Chem. 2000 Jan 7;275(1):29-34
references.pmid: 10617581
references.citation: Leukemia. 2007 Mar;21(3):439-45
references.pmid: 17205056
references.citation: J Cell Sci. 2002 Apr 15;115(Pt 8):1567-74
references.pmid: 11950875
references.citation: Blood. 2009 Jun 25;113(26):6567-71
references.pmid: 19389879
references.citation: Leuk Lymphoma. 2014 Jul;55(7):1625-34
references.pmid: 24144307
references.citation: Blood. 2005 Jul 1;106(1):265-73
references.pmid: 15769897
references.citation: Blood. 2009 Aug 20;114(8):1607-17
references.pmid: 19541823
references.citation: Blood. 2000 Nov 15;96(10):3537-43
references.pmid: 11071652
references.citation: Blood. 1999 May 1;93(9):3074-80
references.pmid: 10216104
references.citation: Haematologica. 2011 Jan;96(1):62-8
references.pmid: 20952518
references.citation: Science. 1998 Aug 28;281(5381):1317-22
references.pmid: 9721090
references.citation: Leuk Lymphoma. 2012 Jun;53(6):1062-7
references.pmid: 22054287
references.citation: Biochem Biophys Res Commun. 2004 Mar 26;316(1):85-92
references.pmid: 15003515
references.citation: Mol Med. 2012 Feb 10;18:19-28
references.pmid: 21979753
references.citation: Anticancer Drugs. 2011 Jan;22(1):79-88
references.pmid: 20881478
references.citation: Leukemia. 2012 Oct;26(10):2176-85
references.pmid: 22614177
references.citation: Biol Blood Marrow Transplant. 2011 Dec;17(12):1874-7
references.pmid: 21767516
references.citation: J Cell Physiol. 2003 Nov;197(2):157-68
references.pmid: 14502555
references.citation: Blood. 2012 May 31;119(22):5133-43
references.pmid: 22368270
references.citation: Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11752-6
references.pmid: 7972136
references.citation: Nat Rev Cancer. 2008 Feb;8(2):121-32
references.pmid: 18202696
references.citation: J Exp Med. 1995 Nov 1;182(5):1545-56
references.pmid: 7595224
references.citation: Blood Cancer J. 2012 Mar;2(3):e60
references.pmid: 22829255
references.citation: J Natl Cancer Inst. 2008 Feb 6;100(3):184-98
references.pmid: 18230792
references.citation: Cell. 1997 Oct 31;91(3):325-34
references.pmid: 9363941
references.citation: Blood. 2002 Sep 1;100(5):1532-42
references.pmid: 12176867
references.citation: Leuk Res. 2010 Oct;34(10):e270-2
references.pmid: 20627386
references.citation: Blood. 2004 Mar 1;103(5):1901-8
references.pmid: 14604973
references.citation: Neuron. 1995 Oct;15(4):961-73
references.pmid: 7576644
references.citation: Jpn J Pharmacol. 1990 Jan;52(1):95-100
references.pmid: 2308240
references.citation: J Clin Oncol. 2011 Aug 20;29(24):3293-300
references.pmid: 21768474
references.citation: Curr Opin Hematol. 2002 Jul;9(4):274-81
references.pmid: 12042700
references.citation: Blood. 2003 Apr 15;101(8):3164-73
references.pmid: 12468433
references.citation: Leuk Lymphoma. 2012 May;53(5):973-81
references.pmid: 22023523
references.citation: Leuk Res. 2008 Nov;32(11):1684-97
references.pmid: 18339423
references.citation: Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):e13-7
references.pmid: 24144836
references.citation: Acta Haematol. 2010;124(3):153-9
references.pmid: 20938170
references.citation: Br J Haematol. 2012 Apr;157(1):131-2
references.pmid: 22050655